Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22502018 | 0.95 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1ACACBACACANQO2 | |
| SCHEMBL22501987 | 0.92 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1ACACBACACANQO2 | |
| SCHEMBL31546947 | 0.92 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1ACACBACACANQO2 | |
| SCHEMBL22502015 | 0.87 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1ACACBACACANQO2 | |
| SCHEMBL26125824 | 0.85 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1ACACBACACANQO2 | |
| SCHEMBL25346727 | 0.83 | HSP90AA1 (0.32) | HSP90AA1HSP90AB1 | |
| SCHEMBL22502038 | 0.80 | STK17B (0.35) | HSP90AA1HSP90AB1ACACBACACA | |
| SCHEMBL30588742 | 0.79 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1ACACBACACANQO2 | |
| SCHEMBL26129010 | 0.79 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1ACACBACACANQO2 | |
| SCHEMBL29600537 | 0.78 | LMNA (0.37) | HSP90AA1HSP90AB1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4335498-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | Vertex Pharmaceuticals Incorporated (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3946595-B1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | VERTEX PHARMA (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3946595-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | Vertex Pharmaceuticals Incorporated (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020206080-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-10-08 | — | — | WO | disclosed |